Volume 16, Issue 2

Volume 16, Issue 2
29April2021

Letter from the ECCO President

Laurent Peyrin-Biroulet, ECCO President


Laurent Peyrin-Biroulet
© ECCO

 

Dear Friends,

I hope that all ECCO Members will be vaccinated when reading this article except maybe a few Y-ECCO Members!

This is the second issue of ECCO News this year and the 16th Congress of ECCO is fastly approaching.

Posted in ECCO News, Letters from the ECCO President, Volume 16, Issue 2

29April2021

ECCO'21 Virtual - Scientific and Educational Programme

The educational programme of the 16th Congress of ECCO is scheduled one week prior to the official start of the ECCO Congress and all educational courses take place from July 2-3, 2021. These activities target ECCO’s different interest groups including young gastroenterologists, surgeons, paediatricians, pathologists, IBD Nurses, dietitians, allied health professionals and scientists.

The scientific programme will be held from July 8-10, 2021 including Digital Oral Presentations. In addition we are pleased to announce that the titles of the abstract oral presentations are already included in the online programme.

An overview of these activities can be found below. In order to get more information please click on the respective course link. For ECCO'21 Virtual overlapping courses can be watched on-demand until end of October 2021. It is foreseen, that delegates who registered for educational courses and/or the scientific programme can claim their CME credits also for on-demand content. We encourage you to register at your earliest convenience.

We look forward to welcoming you at the 16th Congress of ECCO Virtual!

Posted in ECCO News, Congress News, Volume 16, Issue 2, ECCO'21

29April2021

ECCO Grant Study Synopsis: Marleen Bouhuys

Marleen Bouhhuys, ECCO Grant Awardee

De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring (free-study)

Marleen Bouhuys
© Marleen Bouhuys

Aim of research

Treatment outcomes of patients with Inflammatory Bowel Disease (IBD) have improved enormously due to the use of anti-tumour necrosis factor (anti-TNF) agents, but prolonged use comes with disadvantages such as infections and skin problems. Observational studies suggest that dosing interval lengthening can reduce the risk of these adverse reactions in a relevant proportion of patients, provided that they are closely monitored.

The aim of our study is to evaluate whether, in patients with IBD in sustained remission, anti-TNF dosing interval lengthening is non-inferior compared to an unchanged dosing interval with respect to maintenance of target faecal calprotectin (FC) levels.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 16, Issue 2

29April2021

ECCO Grant Study Synopsis: Sudipto Das

Sudipto Das, ECCO Grant Awardee

ROLE OF DNA METHYLATION AND GENE EXPRESSION ALTERATIONS IN DEVELOPMENT OF EARLY-ONSET PRIMARY SCLEROSING CHOLANGITIS IN ULCERATIVE COLITIS – DYNAMIC

Sudipto Das
© Sudipto Das

Aim of research

Primary sclerosing cholangitis (PSC) is a progressive cholestatic disease and up to 80% of PSC patients have Ulcerative Colitis (PSC-UC), which presents a clinical challenge owing to the difficulty in diagnosis and increased risk for development of cancer. While several multifactorial processes, including inflammation and dysbiosis of microbiota, have been associated with PSC-UC pathogenesis, the precise molecular factors that regulate the phenotype of this disease subtype remain unknown. This research project – DYNAMIC – hypothesises that mapping the differences in DNA methylation and gene expression alterations between young PSC-UC and non-PSC-UC patients will allow us to unravel critical molecular factors that underpin this disease subtype.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 16, Issue 2

29April2021

ECCO Grant Study Synopsis: Francesco Giudici

Francesco Giudici, ECCO Grant Awardee

FINE DETERMINATION OF GUT TISSUE LAYERS’ INFLAMMATION EXPLORING IMMUNE-MICROBIOTA SIGNATURES: NEW BIOMARKERS OF RECURRENCE IN SURGICAL PATIENTS WITH CROHN’S DISEASE?

Francesco Giudici
© Francesco Giudici

Aim of research

Up to 65% of patients with Crohn’s Disease (CD) show disease recurrence after ileocolic resection. The reasons for this high recurrence rate are still unclear, but the abnormal CD inflammatory process, against the microbiota, affects all the intestinal wall layers. We aim to explore the mutual interplay of inflammatory and microbial factors involved in CD through a systems-level study, defining the “correlation network” of mucosa-associated microbiota (and its faecal metabolites) at the time of ileocolic resection. We will evaluate whether specific microbial/inflammatory correlations are statistically associated with early postoperative endoscopic recurrence, assessed by colonoscopy at six months.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 16, Issue 2

29April2021

ECCO Grant Study Synopsis: Tobias Schwerd

Tobias Schwerd, ECCO Grant Awardee

TISSUE-ASSOCIATED MICROBIAL AND CELLULAR DRIVERS OF RESOLUTION OF INFLAMMATION AND DISEASE EXACERBATION IN A LONG-TERM COHORT OF PAEDIATRIC CD PATIENTS

Tobias Schwerd
©  Tobias Schwerd

Aim of research

Inflammatory Bowel Diseases (IBD) are characterised by episodes of disease quiescence and disease exacerbation. The microbial and molecular events that result in long-lasting resolution of inflammation or the transition from IBD quiescence (mucosal healing) to active intestinal inflammation are unknown. Intestinal inflammation arises from a dysregulated response of tissue-resident immune cells, such as T cells, towards the intestinal microbiota. We aim to study longitudinal host–microbe interactions at the mucosal level as a strategy to identify microbial and molecular events associated with the resolution or re-activation of intestinal inflammation in individual paediatric patients with IBD.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 16, Issue 2

29April2021

ECCO Grant Study Synopsis: Shai Bel

Shai Bel, ECCO Grant Awardee

THE ROLE OF AUTOPHAGY IN LIMITING IBD-ASSOCIATED AIEC-INDUCED INTESTINAL INFLAMMATION

Shai Bel
© Shai Bel

Aim of research

While the aetiology underlying the development of Inflammatory Bowel Diseases (IBD) is unclear, evidence points to an interaction between host genetics, such as mutations in autophagy genes, and environmental factors, such as bacterial infections. Multiple studies have identified an adherent-invasive Escherichia coli pathotype (AIEC) that attaches to intestinal epithelial cells (IECs) in patients with IBD but not in healthy subjects. It is thought that AIEC exploits the intestinal inflammation in patients with IBD to attach to the IECs, intensifying the pre-existing inflammation. Studies in vitro have shown that functional autophagy is crucial to eliminate AIEC infection. Here, we aim to identify how, and in which compartment of the intestine, autophagy protects the host from AIEC-associated pathologies in vivo and to determine whether artificially enhancing the autophagy process is a viable therapeutic avenue for patients with IBD and intestinal AIEC colonisation.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 16, Issue 2

29April2021

ECCO Grant Study Synopsis: Charlotte Hedin

Charlotte Hedin, ECCO Grant Awardee

DEFINING AND SUPPORTING MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE

Charlotte Hedin
© Charlotte Hedin

Aim of research

One goal of Ulcerative Colitis (UC) treatment is complete endoscopic/histological mucosal healing (MH). The treatments currently used to achieve MH almost universally act through immunosuppression, with side-effects of infection and cancer. Therapeutic strategies that directly promote MH are lacking, partly due to poor understanding of the dynamics and different phases of MH. Better knowledge of the stages of MH may also inform optimal timing of therapeutic interventions.

The aims of this project are to generate an in-depth dynamic molecular characterisation of patients with acute, active UC and to follow the development of this profile into either MH or eventual non-response with consequent surgery. The molecular data will be linked to detailed registration of diet during inflammation and healing and to durability of remission.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 16, Issue 2

29April2021

ECCO Grant Study Synopsis: M. Nabil Quraishi

M. Nabil Quraishi, ECCO Grant Awardee

A SYSTEMS BIOLOGY APPROACH FOR IDENTIFICATION OF HOST AND MICROBIAL MECHANISMS AND DRUGGABLE TARGETS FOR THE TREATMENT OF PSC-IBD

M. Nabil Quraishi
© M. Nabil Quraishi

Aim of research

Primary sclerosing cholangitis (PSC) is a rare hepatobiliary manifestation of Inflammatory Bowel Disease (IBD) that is associated with significant and disproportionate unmet needs and a higher all-cause mortality compared with IBD alone. Unfortunately, no medical therapy has been proven to slow disease progression in PSC-IBD, and liver transplantation is the only life-saving intervention for patients.

We recently identified distinct mucosal transcriptomic profiles in PSC-IBD with regard to bile acid metabolism, bile acid signalling and a central role of enteric dysbiosis. Data from other groups have shown that oral vancomycin attenuates colonic inflammation and improves biochemical markers of cholestasis in PSC. In our study, we hypothesise that oral vancomycin attenuates colonic mucosal inflammation in PSC-IBD by restoring gut microbiota-mediated bile acid homeostatic pathways. We aim to identify druggable gut microbial and host molecular pathways associated with bile acid-mediated colonic mucosal inflammation in PSC-IBD.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 16, Issue 2

29April2021

ECCO Grant Study Synopsis: Roksana Maria Pirzgalska

Roksana Maria Pirzgalska, ECCO Grant Awardee

A NEUROEPITHELIAL APPROACH TO INFLAMMATORY BOWEL DISEASE

Roksana Maria Pirzgalska
© Roksana Maria Pirzgalska

Aim of research

Deregulation of the gut mucosa is an under-appreciated aspect of Inflammatory Bowel Disease (IBD) and metabolic syndrome. We hypothesise that brain-derived signals modulate mucosal physiology by regulating both immune responses in the gut and the absorptive capacity of intestinal cells. We aim to understand the function of this proposed brain–gut circuit and to what extent this information can be harnessed from a clinical perspective.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 16, Issue 2

Portal